Clinical Trial Update: Adjuvant Pembrolizumab for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma at High Risk of Recurrence [Phase 2]

View source ↗

Summary

Phase 2 trial of adjuvant pembrolizumab for locally advanced esophageal squamous cell carcinoma at high risk of recurrence has completed and results have been p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Esophageal Squamous Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-12-19